Core Insights - The article discusses the initiation of a Phase III clinical trial for IBI128, a new generation xanthine oxidase inhibitor, aimed at providing an effective and safe treatment option for millions of gout patients in China [1][6]. Disease Background - Gout is one of the fastest-growing metabolic diseases in China, with a hyperuricemia prevalence rate of 17.7% and a gout prevalence rate of 3.2%, affecting over 177 million people, including tens of millions of gout patients [1][6]. - The disease is increasingly prevalent among younger populations, with nearly 60% of patients aged between 18-35 years, and the average onset age dropping to 48.28 years, linked to high-purine diets, sugary beverage consumption, and sedentary lifestyles [1][6]. Mechanism Innovation - IBI128 is a novel non-purine selective xanthine oxidase inhibitor designed to lower blood uric acid levels by inhibiting the key enzyme xanthine oxidase, aiming for higher selectivity and better safety compared to first-generation and second-generation inhibitors [7][8]. - Current treatments face challenges regarding safety and efficacy, including cardiovascular risks and limitations in clinical application due to hypersensitivity reactions and acute kidney injury risks from high uric acid excretion [2][7]. Phase II Data - The Phase II study (CIBI128A201) results presented at the 2025 Asia Pacific League of Associations for Rheumatology Congress showed an 81% target achievement rate for IBI128 at a 100mg dosage, significantly outperforming the 40mg dose of febuxostat [2][8][9]. - This data indicates that IBI128 has the potential to surpass existing standard treatments in uric acid reduction efficacy [9]. Phase III Study Design - The Phase III study is designed as a randomized, double-blind, multi-center trial, enrolling 600 Chinese patients who meet the 2015 ACR/EULAR gout diagnostic criteria, with a treatment period of one year [3][9]. - The primary endpoint is the proportion of patients achieving blood uric acid levels <360 μmol/L at 24 weeks, with long-term observation to validate treatment benefits [3][9]. Strategic Layout - The company is systematically building its portfolio in the gout and hyperuricemia treatment space, aiming to enhance its competitive edge by offering a comprehensive range of treatment options tailored to different disease stages and patient needs [5][10]. - The ongoing advancements of IBI128 from Phase II to the initiation of Phase III trials are seen as a beacon of hope for gout patients, potentially overcoming existing efficacy and safety limitations of current medications [10].